Clinical trial
Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer
NCT03262103
Study timeline
Study start (actual)2017-06-16Date precision: day
Registry last updated2022-09-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancerunresolved
Interventions
Intratumoral (IT) Poly ICLC 0.5 mgBIOLOGICAL
Intratumoral (IT) Poly ICLC 1.0 mgBIOLOGICAL
Intramuscular (IM) Poly ICLCBIOLOGICAL
Radical ProstatectomyPROCEDURE
Sponsors & collaborators
Ashutosh Kumar Tewarilead sponsor
Oncovir, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03262103 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.